Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?: authors reply.

Gao, Zhen; Huang, Shujie; Wang, Sichao; Tang, Dezhao; Xu, Wei; Zeng, Ruijie; Qiao, Guibin

Gao, Zhen; Huang, Shujie; Wang, Sichao; Tang, Dezhao; Xu, Wei; Zeng, Ruijie; Qiao, Guibin.

Afiliación

Gao Z; Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Huang S; Centre of Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK.
Wang S; Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Tang D; Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Xu W; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Zeng R; Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Qiao G; Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.

Lancet Reg Health West Pac ; 39: 100927, 2023 Oct.

Article en En | MEDLINE | ID: mdl-37868211

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Lancet Reg Health West Pac Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google